Tigecycline Urinary Concentrations
Tigecycline achieves very low urinary concentrations and should not be used for urinary tract infections. Only approximately 22% of the total dose is excreted as unchanged tigecycline in urine, with the primary route of elimination being biliary/fecal excretion (59% of the dose) 1.
Pharmacokinetic Profile in Urine
The renal clearance of tigecycline represents only approximately 20% of total systemic clearance 2. Following standard dosing:
- Renal clearance: 38.0-51.0 mL/min 1
- Urinary recovery: Approximately 13-16% of the administered dose is recovered in urine over 48 hours 3
- Unchanged drug in urine: Only 22% of the total dose is excreted as unchanged tigecycline in urine 1, 4
Clinical Implications for Urinary Tract Infections
Tigecycline is explicitly contraindicated for bacteremia and urinary tract infections due to low serum and urinary concentrations 5. The 2022 guidelines on multidrug-resistant organisms specifically state that "the role of tigecycline in the treatment of bacteremia and urinary tract infection due to CRE is limited due to its low serum and urinary concentration" 5.
Distribution Characteristics
Tigecycline has a very large volume of distribution (500-700 L or 7-9 L/kg), indicating extensive tissue distribution beyond plasma 1. This pharmacokinetic property results in:
- Low serum concentrations: Maximum concentration (Cmax) of only 0.63-0.87 mcg/mL with standard dosing 1
- Minimal urinary penetration: The drug preferentially distributes to tissues rather than remaining in circulation or concentrating in urine 1
Exception: Multidrug-Resistant UTIs
Despite poor urinary concentrations, tigecycline has been used off-label as salvage therapy for complicated UTIs caused by multidrug-resistant organisms when no other options exist 6. A systematic review of 27 case reports showed:
- Clinical/microbiological response: 88.9% (24/27 cases) achieved favorable outcomes 6
- Median treatment duration: 13 days (range 10-15 days) 6
- Recurrence rate: 4 patients experienced symptom recurrence within 3 months 6
- Most common pathogens: Klebsiella pneumoniae, Acinetobacter baumannii, and Escherichia coli 6
Dosing Considerations
No dosage adjustment is required for renal impairment, as tigecycline pharmacokinetics are not significantly altered even in severe renal dysfunction or hemodialysis 1, 2. The drug is not efficiently removed by dialysis and can be administered without regard to timing of hemodialysis 2.
Standard Dosing
- Loading dose: 100 mg IV
- Maintenance dose: 50 mg IV every 12 hours 1
Common Pitfall
The critical error is attempting to use tigecycline for primary treatment of UTIs based solely on in vitro susceptibility testing. While the organism may be susceptible in the laboratory, inadequate urinary drug concentrations make clinical failure likely 5. Tigecycline should only be considered for UTIs when it is the sole susceptible agent available and preferably in combination with other antimicrobials 6.